• AcroMeta to obtain a tactical stake in Macro-ATCLS Pte. Ltd., for the Ambient Temperature Cellular Logistics service.
• Choice to get a special licence to release the Ambient Temperature Cellular Logistics platform throughout Southeast Asia.
• The Group will continue to assess tactical chances that support its long-lasting development.

[L-R] Signing event in between Mr Toh Ker How, Executive Director of AcroMeta Group Limited, and Ms Kawinyarat Mardpiratchata, CFO and Managing Partner of Macro-HRD Pte. Ltd.

SINGAPORE, Sept 7, 2026 – (ACN Newswire)- AcroMeta Group Limited (“AcroMetaor the”Businessand together with its subsidiaries, the” Group”)today revealed that it has actually participated in a non-binding term sheet (“Term Sheet) with Macro HRD SG Pte. Ltd. (“Macro), a Singapore-based company of management consultancy services to the health care sector. The Term Sheet sets out the primary terms for a tactical collaboration in between AcroMeta and Macro-ATCLS Pte. Ltd. (“Macro-ATCLS), the business through which Macro’s Ambient Temperature Cellular Logistics innovation is being commercialised.

Mr Lawrence Toh, Executive Director of AcroMeta Group Limitedstated, “This proposed tactical collaboration provides us the chance to develop a position in a market where cell and gene treatment logistics are anticipated to grow at double-digit rates in the years ahead. We see this as a natural extension of our technique to grow our portfolio beyond our core operations, and we’re thrilled about the prospective to develop a significant existence in bringing this innovation into Southeast Asia.”

About Ambient Temperature Cellular Logistics (ATCLS)

Ambient Temperature Cell Logistics (ATCLS) is an emerging innovation accredited by Macro HRD, created to essentially change the transport and circulation of living cells and other temperature-sensitive biological products by removing reliance on traditional cooled and cryogenic cold chains. ATCLS utilizes exclusive ambient-temperature conservation and reactivation innovations, supported by its exclusive Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance, chain-of-identity and procedure control, making it possible for inactive living cells to be carried at ambient temperature level and reactivated at the point of usage.

The chance addresses quickly broadening markets consisting of stem cells, CAR-T/immune-cell treatment, gene treatment, regenerative medication, organ and tissue transplant, and cell-and-gene-therapy logistics; the hidden markets mentioned in the job products vary from US$ 5.2 billion for immune-cell treatment to US$ 47 billion for organ hair transplantwhile the international cell-and-gene-therapy 3PL market is approximated at US$ 1.81 billion in 2025 and predicted to reach US$ 16.95 billion by 2035 (25.1% CAGR).

Based upon specified ambient-addressable sections, ATCLS approximates a Functional Addressable Market (SAM) of around US$ 14.5 billion by 2032placing the innovation as a prospective category-creating service efficient in lowering the expense, fragility and geographical restrictions of traditional cold-chain logistics. (See Footnote 1)

Proposed Exclusive Licensing Arrangement for Southeast Asia

AcroMeta will have a choice to get a special licence to release the ATCLS innovation throughout predetermined areas in Southeast Asia, consisting of the right to designate sub-licensees. The proposed special licensing plan is planned to supply AcroMeta with the rights to establish and commercialise the ATCLS service within Southeast Asia.

This structure enables AcroMeta to protect unique rights throughout the Southeast Asian markets, together with an initially ideal to get extra areas, substantially broadening the Group’s possible industrial grab the ATCLS innovation.

Structure AcroMeta’s Platform Growth Strategy

The Group means to continue assessing tactical chances to support its long-lasting worth development for investors. The Board stays concentrated on disciplined capital allotment as the Group advances through its next stage of advancement.

Footnote 1: This details was offered by Macro’s management and has actually not been validated by the board of directors. The directors have actually not investigated or confirmed the information provided by the business.

About AcroMeta Group Limited (SGX: 43F)

AcroMeta Group Limited (“AcroMetaor the”Businessand together with its subsidiaries, the”Group), remains in business of center management services. The Company has actually been noted on the Catalist board of the Singapore Exchange because 2016. To find out more, please see www.AcroMeta.com.

About Macro HRD SG Pte. Ltd. (Macro HRD)

Macro HRD is a Singapore-based biotechnology and therapies business developed in 2024, concentrated on establishing scalable, precision-medicine options for high-burden contagious illness with considerable unmet medical requirements.

The business incorporates innovative biology, healing platform innovations and AI/ML-enabled choice systems to speed up drug discovery and translational advancement from clinical research study through medical application. Its advancement portfolio consists of ingenious techniques targeting HIV/AIDS, HPV and other enveloped infections, supported by exclusive restorative and drug-delivery platforms.

Macro HRD combines a worldwide network of clinical, medical, regulative, financial investment and innovation competence, with the objective of equating development science into unique rehabs with significant international health care effect.

Media and Analysts Contact:
Waterbrooks Consultants Pte Ltd
Mr Wayne Koo Tel: +65 9338 8166/ +65 8901 9780
Email: [email protected]
Email: [email protected]

Subject: Press release summary